Patents Assigned to Theratechnologies Inc.
-
Patent number: 9073963Abstract: The invention relates to compositions which are useful for inhibiting prostaglandin F2? receptor. The compositions include, but are not limited to, linear peptides, peptide analogs, and peptidomimetics. Methods of using the compositions of the invention to treat preterm labor and dysmenorrhea are disclosed.Type: GrantFiled: April 15, 2009Date of Patent: July 7, 2015Assignees: Universite De Montreal, Theratechnologies, Inc.Inventors: Krishna Peri, Felix Polyak, William Lubell, Eryk Thouin, Sylvain Chemtob
-
Patent number: 8871713Abstract: Stabilized solid and liquid pharmaceutical formulations comprising a GRF molecule as active ingredient, such as GRF analogs including those comprising an N-terminal-attached hydrophobic moiety, such as [trans-3-hexenoyl]hGHRH (1-44) amide, are disclosed. The formulation comprises a GRF molecule or a pharmaceutically acceptable salt thereof and a ?-cyclodextrin which is not conjugated to the GRF molecule or salt thereof. Also disclosed is the use of the formulation for the treatment of various conditions, methods of preparing the formulation, as well as kits containing it. Methods of stabilizing (e.g., with respect to chemical stability) such GRF molecules, as well as methods of inhibiting their deamidation at Asn8, are also disclosed.Type: GrantFiled: March 14, 2013Date of Patent: October 28, 2014Assignee: Theratechnologies Inc.Inventors: Kirill I Shingel, Daniel Fleury
-
Patent number: 8822413Abstract: A bifunctional hormone exhibiting an alpha-MSH activity and a natriuretic peptide activity is described. The bifunctional hormone comprises for example a first domain having alpha-MSH related hormonal activity covalently linked to a second domain having natriuretic peptide related hormonal activity. The bifunctional hormone of the present invention is useful for example for the prevention and/or treatment of renal related diseases or conditions, such as acute renal failure (ARF) or acute kidney injury (AKI).Type: GrantFiled: July 7, 2008Date of Patent: September 2, 2014Assignee: Theratechnologies Inc.Inventors: Krishna G. Peri, Abdelkrim Habi
-
Patent number: 8481489Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.Type: GrantFiled: September 26, 2008Date of Patent: July 9, 2013Assignee: Theratechnologies Inc.Inventors: Thierry Abribat, Andre De Villers, Alcide Chapdelaine, Soraya Allas, Denis Gravel
-
Patent number: 8435945Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.Type: GrantFiled: September 26, 2008Date of Patent: May 7, 2013Assignee: Theratechnologies Inc.Inventors: Thierry Abribat, Andre De Villers, Alcide Chapdelaine, Soraya Allas, Denis Gravel
-
Patent number: 8361964Abstract: Novel GRF analogs having GRF activity are described herein, as well as uses thereof for example as a GRF receptor agonist, e.g., to induce growth hormone secretion in a subject or biological system.Type: GrantFiled: April 17, 2012Date of Patent: January 29, 2013Assignee: Theratechnologies Inc.Inventors: Krishna G. Peri, Abdelkrim Habi
-
Patent number: 8314066Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.Type: GrantFiled: October 23, 2007Date of Patent: November 20, 2012Assignee: Theratechnologies Inc.Inventors: Thierry Abribat, Andre De Villers, Alcide Chapdelaine, Soraya Allas, Denis Gravel
-
Publication number: 20110105390Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for increasing muscle function in a subject. Also disclosed herein are corresponding methods, packages and compositions.Type: ApplicationFiled: January 11, 2011Publication date: May 5, 2011Applicant: Theratechnologies Inc.Inventors: Bruno LUSSIER, Luc Vachon, Soraya Allas, Thierry Abribat
-
Publication number: 20100087366Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.Type: ApplicationFiled: September 26, 2008Publication date: April 8, 2010Applicant: Theratechnologies Inc.Inventors: Thierry Abribat, Andre De Villers, Soraya Allas, Denis Gravel, Alcide Chapdelaine
-
Patent number: 7538185Abstract: Novel GLP-1 analogs having improved biological potency as well as extended pharmacological activity are described herein. More specifically, the present invention relates to GLP-1 analogs (28 or 29 aa long) comprising amino acid substitutions at one or more of the following positions: 8, 20, 27, 30 and 33.Type: GrantFiled: January 7, 2005Date of Patent: May 26, 2009Assignee: Theratechnologies Inc.Inventors: Krishna Peri, Daniel Abran, Abdelkrim Habi
-
Patent number: 7521530Abstract: The invention relates to compositions which are useful for inhibiting prostaglandin F2?receptor. The compositions include, but are not limited to, linear peptides, peptide analogs, and peptidomimetics. Methods of using the compositions of the invention to treat preterm labor and dysmenorrhea are disclosed.Type: GrantFiled: June 11, 2002Date of Patent: April 21, 2009Assignees: Universite De Montreal, Theratechnologies, Inc.Inventors: Krishna Peri, Felix Polyak, William Lubell, Eryk Thouin, Sylvain Chemtob
-
Publication number: 20090088383Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.Type: ApplicationFiled: September 26, 2008Publication date: April 2, 2009Applicant: Theratechnologies Inc.Inventors: Thierry Abribat, Andre De Villers, Soraya Allas, Denis Gravel, Alcide Chapdlaine
-
Publication number: 20090011997Abstract: A bifunctional hormone exhibiting an alpha-MSH activity and a natriuretic peptide activity is described. The bifunctional hormone comprises for example a first domain having alpha-MSH related hormonal activity covalently linked to a second domain having natriuretic peptide related hormonal activity. The bifunctional hormone of the present invention is useful for example for the prevention and/or treatment of renal related diseases or conditions, such as acute renal failure (ARF) or acute kidney injury (AKI).Type: ApplicationFiled: July 7, 2008Publication date: January 8, 2009Applicant: Theratechnologies Inc.Inventors: Krishna G. Peri, Abdelkrim Habi
-
Publication number: 20090011985Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.Type: ApplicationFiled: October 23, 2007Publication date: January 8, 2009Applicant: Theratechnologies Inc.Inventors: Thierry Abribat, Andre De Villers, Soraya Allas, Denis Gravel, Alcide Chapdelaine
-
Patent number: 7414029Abstract: Antagonistic peptides of prostaglandin E2 receptor subtype EP4 and their use in the treatment or prevention of medical conditions associated with oligouric nephropathy, bone resorption, abnormal intestinal crypt cell proliferation or patency of the ductus arteriosus and the like are provided herein. The antagonistic peptides of the present invention can include the following formula: X-A-RnYm wherein “X” is a hydrogen atom or an amine protecting group producing a carbamate or an amide when reacting with the amine; “A” is L-(4,4?)-biphenylalanine or D-(4,4?)-biphenylalanine; “R” is an amino acid selected from the group consisting of threonine, serine, tyrosine, glutamic acid, alanine, leucine and glycine; “Y” is lysine; “n” is an integer ranging from 5 to 7; and “m” is an integer ranging from 0 to 2.Type: GrantFiled: October 19, 2004Date of Patent: August 19, 2008Assignee: Theratechnologies, Inc.Inventors: Krishna G. Peri, Serge Moffett, Daniel Abran, Annie Bergeron
-
Patent number: 7316997Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.Type: GrantFiled: October 20, 2004Date of Patent: January 8, 2008Assignee: Theratechnologies Inc.Inventors: Thierry Abribat, Andre De Villers, Soraya Allas, Denis Gravel, Alcide Chapdelaine
-
Publication number: 20060292613Abstract: A GPCR-like protein is described, as well as inhibitory/antagonistic compounds and compositions comprising such inhibitors/antagonists of the protein. Such compounds may be used for treating elevated intraocular pressure and conditions associated with elevated intraocular pressure, such as glaucoma.Type: ApplicationFiled: July 12, 2006Publication date: December 28, 2006Applicant: Theratechnologies Inc.Inventors: Krishna Peri, Serge Moffett, Daniel Abran
-
Patent number: 7094761Abstract: A GPCR-like protein is described, as well as inhibitory/antagonistic compounds and compositions comprising such inhibitors/antagonists of the protein. Such compounds may be used for treating elevated intraocular pressure and conditions associated with elevated intraocular pressure, such as glaucoma.Type: GrantFiled: October 28, 2004Date of Patent: August 22, 2006Assignee: Theratechnologies Inc.Inventors: Krishna G. Peri, Serge Moffett, Daniel Abran
-
Patent number: 7067488Abstract: The present invention relates to a GLP-1 peptide having the following formula, or a pharmaceutically acceptable salt thereof: X-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-lle-Ala-Trp-Leu-val-Lys-Gly-Arg-Y (SEQ ID NO. 1) wherein X is a rigidifying hydrophobic moiety and wherein Y is selected from the group consisting of OH, NH2 and Gly-OH. Moreover, the present invention relates to pharmaceutical compositions comprising a therapeutically effective amount of a peptide of the present invention, or a pharmaceutically acceptable salt thereof, in association with at least one constituent selected from a pharmaceutically acceptable carrier, diluent, and excipient.Type: GrantFiled: September 25, 2003Date of Patent: June 27, 2006Assignee: TheraTechnologies Inc.Inventors: Denis Gravel, Krishna Peri, Thierry Abribat, Abdelkrim Habi
-
Publication number: 20050197288Abstract: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.Type: ApplicationFiled: October 20, 2004Publication date: September 8, 2005Applicant: Theratechnologies Inc.Inventors: Thierry Abribat, Andre Villers, Soraya Allas, Denis Gravel, Alcide Chapdelaine